Patents by Inventor Guy Yeoman Krippner
Guy Yeoman Krippner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10172837Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: GrantFiled: September 26, 2016Date of Patent: January 8, 2019Assignee: Naia Metabolic, Inc.Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Publication number: 20170079960Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: ApplicationFiled: September 26, 2016Publication date: March 23, 2017Inventors: Gregory Royce COLLIER, Kenneth Russell WALDER, James Alexander CAMPBELL, Juan-Carlos MOLERO-NAVAJAS, Nicky KONSTANTOPOULOS, Guy Yeoman KRIPPNER
-
Patent number: 9452148Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: GrantFiled: May 31, 2013Date of Patent: September 27, 2016Assignee: Verva Pharmaceuticals LtdInventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Patent number: 9127130Abstract: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogs, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.Type: GrantFiled: August 10, 2007Date of Patent: September 8, 2015Assignees: STARPHARMA PTY LTD., BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LTDInventors: Guy Yeoman Krippner, Zemin Wu, Karlheinz Peter, Christoph Hagemeyer, David Owen
-
Patent number: 8703116Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.Type: GrantFiled: December 21, 2012Date of Patent: April 22, 2014Assignee: Starpharma Pty LimitedInventors: Benjamin James Boyd, Lisa Michelle Kaminskas, Christopher John Hamilton Porter, Peter Karellas, Guy Yeoman Krippner, Pasquale Razzino, Brian Devlin Kelly, Zemin Wu, Sue Pallich
-
Publication number: 20140011848Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: ApplicationFiled: May 31, 2013Publication date: January 9, 2014Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Patent number: 8586705Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: GrantFiled: August 8, 2012Date of Patent: November 19, 2013Assignee: Starpharma Pty LimitedInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex
-
Patent number: 8455432Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: GrantFiled: January 25, 2008Date of Patent: June 4, 2013Assignee: Verva Pharmaceuticals Ltd.Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Patent number: 8420067Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.Type: GrantFiled: August 10, 2007Date of Patent: April 16, 2013Assignee: Starpharma Pty LtdInventors: Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
-
Patent number: 8337823Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.Type: GrantFiled: May 15, 2006Date of Patent: December 25, 2012Assignee: Starpharma Pty LimitedInventors: Benjamin James Boyd, Lisa Michelle Kaminskas, Christopher John Hamilton Porter, Peter Karellas, Guy Yeoman Krippner, Brian Devlin Kelly, Zemin Wu, Pasquale Razzino, Sue Pallich
-
Publication number: 20120302730Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: ApplicationFiled: August 8, 2012Publication date: November 29, 2012Applicant: STARPHARMA PTY LIMITEDInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex
-
Patent number: 8258259Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: GrantFiled: October 25, 2006Date of Patent: September 4, 2012Assignee: Starpharma Pty LimitedInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex
-
Publication number: 20110003740Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: ApplicationFiled: January 25, 2008Publication date: January 6, 2011Applicant: VERVA PHARMACEUTICALS LTD.Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Publication number: 20100292148Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.Type: ApplicationFiled: August 10, 2007Publication date: November 18, 2010Applicant: STARPHARMA PTY LTD.Inventors: Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
-
Publication number: 20100278750Abstract: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.Type: ApplicationFiled: August 10, 2007Publication date: November 4, 2010Applicants: STARPHARMA PTY LTD, BAKER MEDICAL RESEARCH INSTITUTEInventors: Guy Yeoman Krippner, Zemin Wu, Karlheinz Peter, Christoph Hagemeyer, David Owen
-
Publication number: 20090324535Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.Type: ApplicationFiled: May 15, 2006Publication date: December 31, 2009Applicant: Starpharma Pty LtdInventors: Benjamin James Boyd, Lisa Michelle Kaminskas, Christopher John Hamilton Porter, Peter Karellas, Guy Yeoman Krippner, Pasquale Razzino, Brian Devlin Kelly, Zemin Wu, Sue Pallich
-
Publication number: 20090118467Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: ApplicationFiled: October 25, 2006Publication date: May 7, 2009Applicant: Starpharma Pty LimitedInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex